Axogen (AXGN) Insider Weiler Kathy Johnson Buys 4,392 Shares

Weiler Kathy Johnson bought 4,392 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 24, 2026. At a price of $44.93 per share, this purchase is valued at about $197,000. This move reflects growing confidence among insiders in Axogen's future.

Inside Weiler Kathy Johnson's Trade

Kathy Johnson's recent trade adds to a wave of insider purchases at Axogen on the same day. Other insiders, including Alan Levine, John Johnson, and William Burke, also bought 4,392 shares each on June 24, 2026. With a consistent purchase price of zero listed, these insider transactions suggest a strong commitment to the company's direction.

Other Institutional Activity in Axogen, Inc.

Several institutional investors have recently adjusted their stakes in Axogen. Blackrock Inc. increased its holdings by 548,482 shares, bringing its total to 4,419,208 shares valued at approximately $153.8 million. Meanwhile, Morgan Stanley trimmed its position by 375,072 shares, now holding 2,747,924 shares worth about $95.7 million. First Light Asset Management also reduced its stake significantly by 1,254,495 shares, ending with 2,748,361 shares valued at approximately $95.7 million. In contrast, Artemis Investment Management increased its holdings by 384,245 shares, reaching 1,780,992 shares worth about $62 million.

Axogen, Inc. Stock Up 1.6%

Axogen's stock closed at $44.93 on the day of Johnson's purchase, which is just above its 50-day moving average of $45.28. The stock's recent performance has been notable, especially as it trades considerably higher than its 52-week low of $15.27. Investors will be watching how this insider buying influences market sentiment moving forward.

Recent Earnings

In its latest earnings report, Axogen posted revenue of $251.2 million, reflecting a 23.1% growth year-over-year. The company has faced challenges, reporting a net margin of -13.4% and an EPS of -0.67. Axogen's next earnings date is set for October 28, 2026, and may provide further insights into its financial health.

Analysts Set New Price Targets

On October 12, 2026, B of A Securities initiated coverage on Axogen with a 'Buy' rating and a target price of $52.00. Barclays also initiated coverage on October 7, giving the stock an 'Overweight' rating with a target of $55.00. Truist Securities maintained its 'Buy' rating on October 1 with a target of $53.00, while Raymond James rated it 'Outperform' with a target of $53.00 on September 25.

About Axogen, Inc.

Axogen, Inc. specializes in developing technologies for peripheral nerve regeneration and repair. It operates in the healthcare sector, specifically within the medical devices industry. This insider buying trend indicates a strong belief in the company's growth potential, especially in light of its recent performance and upcoming earnings announcement.

Bottom Line

The recent insider purchases at Axogen reflect a positive outlook from management amid ongoing market activity. Investors should keep an eye on the upcoming earnings date of October 28, 2026, and any further insider trades. The reported activity is based on a recent 13F filing which may not represent current positions for these insiders or funds.